7.79

3.59% 0.27

After Hours: 7.79

Foghorn Therapeutics Inc (FHTX)

Overview News Price History Option Chain Financials Why FHTX Down? Discussions Forecast

Foghorn Therapeutics Inc stock is traded at $7.79, with a volume of 66,786. It is up +3.59% in the last 24 hours and up +0.91% over the past month. Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Previous Close:

$7.52

Open:

$7.51

24h Volume:

66,786

Relative Volume:

0.44

Market Cap:

$428.62M

Revenue:

$34.16M

Net Income/Loss:

$-98.43M

P/E Ratio:

-2.8431

EPS:

-2.74

Net Cash Flow:

$-119.33M

1W Performance:

-0.89%

1M Performance:

+0.91%

6M Performance:

+38.12%

1Y Performance:

+79.08%

1-Day Range:

$7.51

$7.89

1-Week Range:

$7.51

$8.425

52-Week Range:

$2.70

$10.25

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

Name

Foghorn Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

617-586-3100

Address

500 TECHNOLOGY SQUARE, CAMBRIDGE

Employee

116

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

FHTX's Discussions on Twitter

Compare FHTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FHTX Foghorn Therapeutics Inc	7.79	428.62M	34.16M	-98.43M	-119.33M	-2.74
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-03-24	Initiated	Jefferies	Buy
Aug-19-24	Initiated	Evercore ISI	Outperform
Mar-28-23	Initiated	BofA Securities	Buy
Jan-05-23	Initiated	BMO Capital Markets	Outperform
Nov-22-21	Initiated	H.C. Wainwright	Buy
Nov-17-20	Initiated	Cowen	Outperform
Nov-17-20	Initiated	Goldman	Buy
Nov-17-20	Initiated	Morgan Stanley	Overweight
Nov-17-20	Initiated	Wedbush	Outperform

View All

Foghorn Therapeutics Inc Stock (FHTX) Latest News

Nov 25, 2024

Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High? - Yahoo Finance

Nov 25, 2024

Nov 19, 2024

(FHTX) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 19, 2024

Nov 18, 2024

Foghorn Therapeutics patents new CBP degradation inducers - BioWorld Online

Nov 18, 2024

Nov 13, 2024

Foghorn Therapeutics (FHTX) Collaborates with Eli Lilly and Surpasses Q3 Expectations - Nasdaq

Nov 13, 2024

Nov 12, 2024

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - The Manila Times

Nov 12, 2024

Nov 08, 2024

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think - Simply Wall St

Nov 07, 2024

Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter Report - Yahoo Finance

Nov 07, 2024

Research Analysts Issue Forecasts for FHTX FY2024 Earnings - MarketBeat

Nov 07, 2024

HC Wainwright Has Bullish Estimate for FHTX FY2024 Earnings - MarketBeat

Nov 07, 2024

Nov 06, 2024

We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully - Yahoo Finance

Nov 06, 2024